Research Analysts Set Expectations for ACAD FY2025 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst C. Duncan now expects that the biopharmaceutical company will earn $0.51 per share for the year, down from their previous forecast of $0.59. Cantor Fitzgerald currently has a “Overweight” rating and a $28.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share.

Several other equities research analysts also recently commented on ACAD. StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday. Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “hold” rating and a $22.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. UBS Group cut their target price on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, April 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 8th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $24.70.

ACADIA Pharmaceuticals Stock Up 0.5%

NASDAQ ACAD opened at $17.52 on Monday. The company has a market cap of $2.93 billion, a PE ratio of 22.46 and a beta of 0.47. ACADIA Pharmaceuticals has a 52 week low of $13.40 and a 52 week high of $20.68. The firm’s 50-day simple moving average is $15.82 and its two-hundred day simple moving average is $17.00.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. The company had revenue of $244.32 million for the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ACAD. Exchange Traded Concepts LLC bought a new stake in ACADIA Pharmaceuticals in the first quarter worth $29,000. Picton Mahoney Asset Management purchased a new stake in ACADIA Pharmaceuticals in the first quarter worth about $32,000. Federated Hermes Inc. lifted its stake in ACADIA Pharmaceuticals by 231.5% in the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 1,618 shares during the period. Virtus Fund Advisers LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at about $39,000. Finally, R Squared Ltd purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at about $47,000. Institutional investors own 96.71% of the company’s stock.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Mark C. Schneyer sold 3,171 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the sale, the executive vice president now owns 56,889 shares in the company, valued at $969,957.45. This trade represents a 5.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. The trade was a 21.85% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,994 shares of company stock worth $313,131. Company insiders own 26.50% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.